Orlowski, R. Z., Dimopoulos, M. A., Leleu, X., Facon, T., Ishida, T., Hajek, R., Špička, I., Romejko-Jarosińska, J., Vorobyev, V., Besemer, B., Beşışık, S. K., Robak, P., Jelinek, T., Goldschmidt, H., Martin, T., Mohty, M., Macé, S., Kodas, E., Tekle, C., Shafer, A. T., Moreau, P. (2026). Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study. Blood. https://doi.org/10.1182/blood.2025030120